Cure8 news brief
A new dual-targeting combination (IL-23 + α4β7) showed higher endoscopic remission rates than either drug alone in a Phase IIa Crohn's study, suggesting a potential new approach for patients who need better mucosal healing. This could matter for people who have incomplete response to single-agent biologics.
Adults with moderate-to-severe Crohn's disease, patients on or considering biologic therapy (especially IL-23 or anti-integrin drugs), gastroenterologists, and IBD researchers.
AbbVie reported Phase IIa TARGET-CD results showing that ABBV-466, a combination of risankizumab (anti–IL-23 p19) plus trosunilimab (α4β7 inhibitor), met the trial's primary endoscopic remission endpoint at Week 12 and showed higher remission rates at Week 24 compared with either monotherapy.
The study is an open-label, randomized, treat-through platform with ~300 patients; safety events were numerically similar across arms with serious adverse events reported in ~9–10% of patients.
What the article reports: ABBV-466 achieved 30.2% endoscopic remission at Week 12 and 40.5% at Week 24 versus lower rates for risankizumab and trosunilimab monotherapy. Gene-expression analyses cited by the company suggested signals of epithelial repair and tissue remodeling with the combination.
Results were described as ongoing and are being presented at UEG Week 2026. What this does not tell you: These are interim, open-label Phase IIa data from a company press-type report; the article does not provide full numerical gene-expression results, independent peer review, or long-term outcomes.
Decisions about treatment should be made with a treating clinician.
The TARGET-CD study is open-label and ongoing (Phase IIa); reported remission differences are modest and company-provided. Safety and longer-term efficacy require confirmation in larger, blinded trials and peer-reviewed publication.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Mid-stage data suggest a dual-targeting approach may improve endoscopic remission for people with moderate–severe Crohn's disease, including many who previously failed advanced therapies. If confirmed in larger trials,...
This trial tests several targeted therapies (including risankizumab) alone and in combination for adults with moderate to severe Crohn's disease, aiming to measure endoscopic remission and safety. Positive findings could...
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
